MabCure, Inc. Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand

NEW YORK--(BUSINESS WIRE)--MabCure, Inc. (OTCBB:MBCI), a leading developer of antibody based diagnostics and treatments for ovarian, prostate and other cancers today announced that it has recently completed its prospective diagnostic clinical study of 150 patients presenting with pelvic mass. The study provides invaluable blood and urine specimen which will be analyzed by MabCure diagnostic antibodies for the detection of Ovarian Cancer. The test was conducted in the Ramathibodi Hospital and the Thai National Cancer Institute, Bangkok, Thailand.